Targeting immunosuppression by Tregs with monoclonal antibodies against GARP.

ABSTRACTReducing Treg function in cancer patients should augment antitumor immune responses. We recently uncovered a mechanism of immunosuppression by human Tregs that implies transmembrane protein GARP and production of active TGF-s1. We obtained monoclonal antibodies that block this process and could thus serve as a novel approach for cancer immunotherapy.